Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Capital Expenditures (2020 - 2025)

Maxcyte (MXCT) has disclosed Capital Expenditures for 6 consecutive years, with $1.7 million as the latest value for Q4 2025.

  • Quarterly Capital Expenditures rose 7.61% to $1.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.8 million through Dec 2025, up 7.09% year-over-year, with the annual reading at $1.8 million for FY2025, 7.09% up from the prior year.
  • Capital Expenditures for Q4 2025 was $1.7 million at Maxcyte, up from -$62000.0 in the prior quarter.
  • The five-year high for Capital Expenditures was $12.8 million in Q2 2022, with the low at -$15.9 million in Q4 2022.
  • Average Capital Expenditures over 5 years is $232220.0, with a median of $53600.0 recorded in 2022.
  • The sharpest move saw Capital Expenditures tumbled 11275.57% in 2022, then soared 3981.25% in 2025.
  • Over 5 years, Capital Expenditures stood at $142450.0 in 2021, then crashed by 11275.57% to -$15.9 million in 2022, then soared by 101.75% to $279000.0 in 2023, then soared by 479.21% to $1.6 million in 2024, then rose by 7.61% to $1.7 million in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $1.7 million, -$62000.0, and -$562000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.